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IMPORTANCE Geographic atrophy (GA) secondary to age-related macular degeneration is a
leading cause of visual disability in older individuals. A phase 2 trial suggested that
lampalizumab, a selective complement factor D inhibitor, reduced the rate of GA
enlargement, warranting phase 3 trials.
OBJECTIVE To assess the safety and efficacy of lampalizumab vs sham procedure on
enlargement of GA.
DESIGN, SETTING, AND PARTICIPANTS Two identically designed phase 3 double-masked,
randomized, sham-controlled clinical trials, Chroma and Spectri, enrolled participants from
August 28, 2014, to October 6, 2016, at 275 sites in 23 countries. Participants were aged 50
years or older, with bilateral GA and no prior or active choroidal neovascularization in either
eye and GA lesions in the study eye measuring 2.54 to 17.78 mm2 with diffuse or banded
fundus autofluorescence patterns.
INTERVENTIONS Participants were randomized 2:1:2:1 to receive 10 mg of intravitreous
lampalizumab every 4 weeks, sham procedure every 4 weeks, 10 mg of lampalizumab every
6 weeks, or sham procedure every 6 weeks, through 96 weeks.
MAIN OUTCOMES AND MEASURES Safety and efficacy assessed as mean change from baseline
in GA lesion area at week 48 from centrally read fundus autofluorescence images of the
lampalizumab arms vs pooled sham arms, in the intent-to-treat population and by
complement factor I–profile genetic biomarker.
RESULTS A total of 906 participants (553 women and 353 men; mean [SD] age, 78.1 [8.1]
years) were enrolled in Chroma and 975 participants (578 women and 397 men; mean [SD]
age, 77.9 [8.1] years) were enrolled in Spectri; 1733 of the 1881 participants (92.1%) completed
the studies through 48 weeks. The adjusted mean increases in GA lesion area from baseline at
week 48 were 1.93 to 2.09 mm2 across all groups in both studies. Differences in adjusted
mean change in GA lesion area (lampalizumab minus sham) were −0.02 mm2 (95% CI, −0.21
to 0.16 mm2; P = .80) for lampalizumab every 4 weeks in Chroma, 0.16 mm2 (95% CI,
0.00-0.31 mm2; P = .048) for lampalizumab every 4 weeks in Spectri, 0.05 mm2 (95% CI,
−0.13 to 0.24 mm2; P = .59) for lampalizumab every 6 weeks in Chroma, and 0.09 mm2 (95%
CI, −0.07 to 0.24 mm2; P = .27) for lampalizumab every 6 weeks in Spectri. No benefit of
lampalizumab was observed across prespecified subgroups, including by complement factor
I–profile biomarker. Endophthalmitis occurred after 5 of 12 447 injections (0.04%) or in 5 of
1252 treated participants (0.4%) through week 48.
CONCLUSIONS AND RELEVANCE In Chroma and Spectri, the largest studies of GA conducted to
date, lampalizumab did not reduce GA enlargement vs sham during 48 weeks of treatment.
Results highlight the substantial and consistent enlargement of GA, at a mean of
approximately 2 mm2 per year.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02247479 and NCT02247531
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G eographic atrophy (GA), an advanced form of age-related macular degeneration (AMD), is a leadingcause of visual disability in elderly individuals,1-3
with prevalence increasing substantially among those older
than 75 years of age.2,3 No approved treatment slows or
halts the progression of GA, or reverses the associated loss
of macular tissue. In contrast, neovascular AMD, the other
form of advanced AMD, is often treated successfully with
intravitreous anti–vascular endothelial growth factor (anti-
VEGF) medications.4-6 Similarly, the Age-Related Eye Dis-
ease Study7 and the Age-Related Eye Disease Study 28
reported that dietary supplements reduce the risk of devel-
oping advanced neovascular AMD but have no apparent
effect on GA.
Occurrence and enlargement of GA lesions can result in
substantial visual disability.9-11 Because lesions typically first
appear outside the fovea,11-13 testing of best-corrected visual
acuity (BCVA) may inadequately assess functional impair-
ment in individuals with preserved foveal function despite
loss of pericentral macula.14 Other measures, including low-
luminance visual acuity, reading speed, fundus-controlled
microperimetry, and patient-reported outcomes, might
assess impairment of visual function in patients with
GA,15,16 but these measures were not extensively used in
earlier GA trials.
Although the pathophysiology of GA is incompletely un-
derstood, dysregulation of the complement cascade, a com-
ponent of the innate immune system,17,18 has been impli-
cated in AMD19,20 and in GA specifically.21 Overall, genetic
factors are estimated to account for 71% to 80% of the risk of
advanced AMD,22,23 and common genetic variants near CFH,
CFI, C3, and C2/CFB, which act in the alternative comple-
ment pathway, may account for 57% of known disease risk
variants.20
Given this genetic link, complement factor D was
selected as a therapeutic target because it is the rate-limiting
enzyme of the alternative complement pathway and is
present in comparatively low abundance.24-26 Lampali-
zumab is an antigen-binding fragment of a humanized
monoclonal antibody that is directed against, and inhibits,
complement factor D.27,28 In a phase 2 trial, monthly intra-
vitreous lampalizumab, 10 mg (n = 42), reduced the mean
enlargement of GA lesion area from baseline to 18 months
by 20% (80% CI, 4%-37%; P = .12) vs sham (n = 40).29 In an
exploratory subgroup analysis of carriers of the comple-
ment factor I (CFI) risk allele, monthly lampalizumab
reduced the enlargement of GA by 44% vs sham.29 No ben-
efit was observed with lampalizumab treatment every 8
weeks.
To test phase 2 observations, we conducted 2 identi-
cally designed phase 3 randomized clinical trials, Chroma
and Spectri, to assess the efficacy and safety of 10 mg of
lampalizumab administered by intravitreal injection every 4
or 6 weeks vs sham treatment. These studies also prospec-
tively investigated the prognostic and predictive diagnostic
hypothesis of the CFI profile genetic biomarker. The
48-week primary outcome of these trials is presented
herein.
Methods
The Chroma (trial protocol and statistical analysis plan are
available in Supplement 1) and Spectri (trial protocol and
statistical analysis plan are available in Supplement 2) stud-
ies were identically designed, phase 3 double-masked, mul-
ticenter, randomized, sham injection–controlled clinical
trials at 131 (Chroma) and 144 (Spectri) sites in 23 countries.
The studies adhered to the tenets of the Declaration of
Helsinki30 and were conducted in accordance with the
International Conference on Harmonisation E6 Guidelines
for Good Clinical Practice31 and with applicable local, state,
and federal laws. All sites received institutional review
board or ethics committee approval before study initiation
(eAppendix 1 in Supplement 3). Participants provided writ-
ten informed consent. An independent data monitoring
committee provided ongoing oversight. Key aspects of the
study design are described herein and in eAppendix 2 in
Supplement 3.
Study Population
Eligible participants (eTable 1 in Supplement 3) were aged
50 years or older with bilateral GA secondary to AMD and
no evidence of active or prior choroidal neovascularization
(CNV) nor previous treatment for CNV in either eye. Key
study eye inclusion criteria were a total GA lesion size
from 2.54 to 17.78 mm2 (1-7 disc areas) measured on blue-
light fundus autofluorescence, as confirmed by the reading
center; perilesional banded or diffuse autofluorescence
patterns; and an Early Treatment Diabetic Retinopathy
Study (ETDRS) BCVA letter score of 49 or more (Snellen
equivalent, 20/100 or better). Geographic atrophy lesions
could be multifocal or unifocal, but at least 1 lesion had
to be 1.27 mm2 or larger (≥0.5 disc areas). In study eyes
with a BCVA letter score of 79 or more (Snellen equivalent,
20/25 or better), at least 1 lesion was required within
250 μm of the foveal center. One eye was selected as
the study eye. If both eyes were eligible, the eye with the
poorer visual function as determined by the investigator
and the patient was selected, followed by the eye with the
Key Points
Question Does lampalizumab, a selective complement factor D
inhibitor, reduce enlargement of lesions from geographic atrophy
secondary to age-related macular degeneration?
Findings In 2 phase 3 randomized clinical trials (906 Chroma
participants and 975 Spectri participants), no meaningful
differences in the primary end point of mean change from baseline
in geographic atrophy lesion area at week 48 were identified
among eyes receiving 10-mg lampalizumab intravitreal injections
either every 4 weeks or every 6 weeks vs sham.
Meaning These phase 3 trials showed that lampalizumab was
ineffective as a treatment of geographic atrophy secondary to
age-related macular degeneration.
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larger GA lesion. Participants were also evaluated at screen-
ing for CFI-profile genetic biomarker status (eTable 2 in
Supplement 3).
Randomization
Participants were randomly assigned 2:1:2:1 to receive 10 mg
of lampalizumab every 4 weeks, sham procedure every 4
weeks, 10 mg of lampalizumab every 6 weeks, and sham pro-
cedure every 6 weeks, via an interactive voice and web re-
sponse system. In the sham groups, the eye was prepped in a
manner similar to lampalizumab groups to preserve mask-
ing, including subconjunctival anesthesia. However, instead
of an actual intravitreal injection, only the hub of a syringe was
placed against the planned injection site. For randomization,
a permuted block design was used, and participants were strati-
fied by CFI-profile biomarker status, baseline BCVA ETDRS
chart Snellen equivalent (20/50 or better vs worse than 20/
50), sex, and eligibility for microperimetry. Participant num-
bers were capped by CFI-profile biomarker status to achieve
a 3:2 ratio for CFI-positive to CFI-negative participants. Sham
arms were pooled for analysis, resulting in a 1:1:1 ratio for lam-
palizumab every 4 weeks, lampalizumab every 6 weeks, and
sham.
Study Treatment and Assessments
Treatment was administered to the study eye at randomiza-
tion (day 1) and every 4 or 6 weeks (±5 days) thereafter through
44 weeks for groups receiving treatment every 4 weeks or 42
weeks for groups receiving treatment every 6 weeks, before
week 48 primary efficacy assessments, continuing through 90
or 92 weeks per study design. Safety and ocular assessments,
including BCVA, were performed at day 8 and at each subse-
quent visit on the same day as treatment. Verbatim descrip-
tions of adverse events (AEs) were coded using Medical Dic-
tionary for Regulatory Activities, version 20.0.32 Fundus images
of both eyes at screening and specified visits were evaluated
at the Doheny Image Reading Center (Los Angeles, Califor-
nia). Autofluorescence pattern eligibility was determined by
the GRADE Reading Center (Bonn, Germany). Additional vi-
sual function assessments were performed as scheduled.
Outcomes
The primary efficacy outcome was mean change in GA lesion
area from baseline to week 48 measured by fundus autofluo-
rescence, graded at the reading center. Secondary efficacy out-
comes assessing visual function were exploratory at week 48,
with formal statistical testing planned at week 96. Safety out-
comes were assessed through a summary of ocular and non-
ocular AEs, deaths, results of serial electrocardiograms (se-
lected participants), incidence of antidrug antibodies, and
ocular assessments.
Statistical Analysis
For each study, a sample size of 188 CFI-positive participants
per lampalizumab treatment arm and 94 CFI-positive par-
ticipants per sham arm provided greater than 95% power to
detect a difference in change in GA lesion area assuming a
population difference of 1.45 mm2 (approximately 40%
reduction relative to sham control) and an SD of 2.51 in the
CFI-positive population. A sample size of 124 CFI-negative
participants per lampalizumab treatment arm and 62 CFI-
negative participants per sham arm provided 80% power to
detect a difference assuming a population difference of 0.66
mm2 (approximately 40% reduction relative to control) and
an SD of 1.68 in the CFI-negative population (eTable 3 in
Supplement 3). Calculations were based on 2-sided t tests at
the α = .0495 level with the assumption of a 15% dropout
rate by week 48.
The primary efficacy analysis for comparison between each
lampalizumab arm and the pooled sham arms was performed
on the intent-to-treat population (all randomized partici-
pants) using a mixed effects model repeated-measures model
based on available data to week 48, with no imputation for
missing data. Change-from-baseline analysis excluded par-
ticipants without a baseline measurement or at least 1 post-
baseline measurement. The primary analysis adjusted for base-
line GA lesion area, subfoveal vs nonsubfoveal location, and
multifocal vs nonmultifocal configuration; CFI-profile bio-
marker status; BCVA (better than vs worse than 20/50 Snel-
len equivalent); and sex. Preplanned subgroup analyses by CFI-
profile biomarker were performed similarly, except with the
model fit separately for each biomarker group and without bio-
marker status as a covariate. Hypothesis testing was per-
formed at a 2-sided α = .0496 level to account for a 0.0001
nominal penalty for each of 4 planned independent data moni-
toring committee unmasked data reviews occurring before the
primary analysis.
To assess robustness of the primary efficacy results, ad-
ditional analyses included the growth slope of the GA lesion
area over 48 weeks, the change from baseline in the square root
of the GA lesion area at week 48, and the percentage change
from baseline in the GA lesion area at week 48. Exploratory
analyses by prespecified clinical subgroup were performed
using mixed effects model repeated-measures analysis simi-
lar to the primary efficacy analysis, excluding baseline covar-
iates not relevant for the particular subgroup. Safety analyses
were performed on the population that received 1 or more doses
of lampalizumab or sham, grouped according to actual treat-
ment received regardless of assignment. Analyses were per-
formed using SAS, version 9.4 (SAS Institute), separately by
study and based on pooled data from Chroma and Spectri,
which included an additional covariate adjustment for study,
as appropriate.
Results
Between August 28, 2014, and October 6, 2016, 906 Chroma
participants and 975 Spectri participants were randomized to
receive sham every 4 weeks (153 Chroma participants; 161 Spec-
tri participants), lampalizumab every 4 weeks (298 Chroma par-
ticipants; 330 Spectri participants), sham every 6 weeks (152
Chroma participants; 160 Spectri participants), or lampali-
zumab every 6 weeks (303 Chroma participants; 324 Spectri
participants) (Figure 1). The baseline demographic character-
istics of the participants (Table 1 and eTables 4 and 5 in
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Supplement 3) were well balanced across treatment groups
(mean [SD] age of 78.0 [8.1] years, 1131 [60.1%] female, and 1827
[97.1%] white). The mean baseline GA lesion area was be-
tween 7.55 and 8.50 mm2 across treatment groups. The mean
Figure 1. CONSORT Flow Diagram for Chroma and Spectri Randomized Clinical Trials
2284 Patients assessed for eligibility
1378 Excluded for not meeting inclusion criteria
906 Randomized
ChromaA
287 Included in primary analysis
16 Excluded from primary analysis
1 Missing data on baseline
GA area
15 Missing data on
postbaseline GA area
146 Included in primary analysis
6 Excluded from primary analysis
(missing data on postbaseline
GA area)
279 Included in primary analysis
19 Excluded from primary analysis
(missing data on postbaseline
GA area)
146 Included in primary analysis
7 Excluded from primary analysis
(missing data on postbaseline
GA area)
303 Randomized to lampalizumab q6w
301 Received intervention as
randomized (99.3%)




152 Randomized to sham q6w
151 Received intervention as
randomized (99.3%)
1 Did not receive intervention
as randomized
298 Randomized to lampalizumab q4w
296 Received intervention as
randomized (99.3%)
2 Did not receive intervention
as randomized
153 Randomized to sham q4w
153 Received intervention as
randomized (100%)
22 Discontinued study before 48
wk (7.3%)
11 Withdrawal by participant (3.6%)
3 Adverse event (1.0%)
3 Death (1.0%)
2 Other (0.7%)
1 Lost to follow-up (0.3%)
1 Physician decision (0.3%)
1 Noncompliance (0.3%)
11 Discontinued study before 48
wk (7.2%)
7 Withdrawal by participant (4.6%)
1 Adverse event (0.7%)
2 Death (1.3%)
1 Other (0.7%)
28 Discontinued study before 48
wk (9.4%)
18 Withdrawal by participant (6.0%)
5 Adverse event (1.7%)
2 Death (0.7%)
2 Other (0.7%)
1 Lost to follow-up (0.3%)
10 Discontinued study before 48
wk (6.5%)
5 Withdrawal by participant (3.3%)
2 Adverse event (1.3%)
1 Lost to follow-up (0.7%)
1 Physician decision (0.7%)
1 Status unknown (0.7%)
2307 Patients assessed for eligibility
1332 Excluded




317 Included in primary analysis
7 Excluded from primary analysis
(missing data on postbaseline
GA area)
155 Included in primary analysis
5 Excluded from primary analysis
(missing data on postbaseline
GA area)
306 Included in primary analysis
24 Excluded from primary analysis
(missing data on postbaseline
GA area)
151 Included in primary analysis
10 Excluded from primary analysis
(missing data on postbaseline
GA area)
324 Randomized to lampalizumab q6w
323 Received intervention as
randomized (99.7%)
1 Did not receive intervention
as randomized
160 Randomized to sham q6w
158 Received intervention as
randomized (98.8%)
2 Did not receive intervention
as randomized
330 Randomized to lampalizumab q4w
329 Received intervention as
randomized (99.7%)
1 Did not receive intervention
as randomized (physician’s
decision)
161 Randomized to sham q4w
160 Received intervention as
randomized (99.4%)
1 Did not receive intervention
as randomized
23 Discontinued study before 48
wk (7.1%)
12 Withdrawal by participant (3.7%)
4 Adverse event (1.2%)
1 Death (0.3%)
3 Other (0.9%)
1 Physician decision (0.3%)
2 Status unknown (0.6%)
8 Discontinued study before 48
wk (5.0%)
5 Withdrawal by participant (3.1%)
1 Death (0.6%)
1 Other (0.6%)
1 Status unknown (0.6%)
31 Discontinued study before 48
wk (9.4%)
20 Withdrawal by participant (6.1%)
4 Death (1.2%)
1 Adverse event (0.3%)
1 Other (0.3%)
2 Noncompliance (0.6%)
2 Lost to follow-up (0.6%)
1 Physician decision (0.3%)
15 Discontinued study before 48
wk (9.3%)
7 Withdrawal by participant (4.3%)
3 Death (1.9%)
3 Adverse event (1.9%)
1 Other (0.6%)
1 Noncompliance (0.6%)
GA indicates geographic atrophy; q4w, every 4 weeks; and q6w, every 6 weeks.
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baseline BCVA letter score was between 65 and 66 (approxi-
mate Snellen equivalent, 20/50) in each group.
A total of 1733 of 1881 participants (92.1%) in Chroma and
Spectri completed the first 48 weeks of the study, during which
across treatment arms more than 76% of participants receiv-
ing treatment every 4 weeks received at least 12 injections (13
possible) and more than 85% of participants receiving treat-
ment every 6 weeks received at least 8 injections (9 possible)
(eAppendix 3 in Supplement 3).
After the Spectri primary analysis in September 2017, lam-
palizumab treatment was suspended for both studies at the
sponsor’s recommendation with the agreement of the chair of
the independent data monitoring committee because the ap-
parent lack of efficacy did not warrant continued intravitreal
injections.
Efficacy of Lampalizumab Treatment
GA Enlargement
At week 48, the adjusted mean increase in GA lesion area from
baseline was 1.93 to 2.09 mm2 across all groups in both stud-
ies (Table 2, Figure 2A, and eFigure 1A-B in Supplement 3). The
differences in the adjusted mean change of the GA lesion area
(lampalizumab minus sham) were −0.02 mm2 (95% CI, −0.21
to 0.16 mm2; P = .80) for lampalizumab every 4 weeks in
Table 1. Pooled Demographic and Baseline Characteristics of Chroma and Spectri Participants
Characteristic
Sham Lampalizumab, 10 mg
All (N = 1881)q4w (n = 314) q6w (n = 312) Pooled (n = 626) q4w (n = 628) q6w (n = 627)
Demographics
Age, y
Mean (SD) 78.1 (8.1) 78.0 (7.9) 78.0 (8.0) 77.4 (7.9) 78.5 (8.3) 78.0 (8.1)
Median (range) 78 (51-96) 78 (51-95) 78 (51-96) 78 (50-95) 80 (53-97) 79 (50-97)
Female sex, No. (%) 187 (59.6) 190 (60.9) 377 (60.2) 379 (60.4) 375 (59.8) 1131 (60.1)
White race, No. (%)a 306 (97.5) 302 (96.8) 608 (97.1) 608 (96.8) 611 (97.4) 1827 (97.1)
Tobacco use, No. (%)
Never 153 (48.7) 136 (43.6) 289 (46.2) 293 (46.7) 290 (46.3) 872 (46.4)
Previous 147 (46.8) 155 (49.7) 302 (48.2) 295 (47.0) 295 (47.0) 892 (47.4)
Current 14 (4.5) 21 (6.7) 35 (5.6) 40 (6.4) 42 (6.7) 117 (6.2)
Study eye baseline characteristics
GA area,b mm2













GA lesion contiguity, No. (%)b
Multifocal 238 (75.8) 253 (81.1) 491 (78.4) 496 (79.0) 477 (76.2) 1464 (77.9)
Nonmultifocal 76 (24.2) 59 (18.9) 135 (21.6) 132 (21.0) 149 (23.8) 416 (22.1)
GA lesion location, No. (%)b
Subfoveal 172 (54.8) 166 (53.2) 338 (54.0) 329 (52.4) 320 (51.1) 987 (52.5)
Nonsubfoveal 142 (45.2) 146 (46.8) 288 (46.0) 299 (47.6) 306 (48.9) 893 (47.5)
Hyperautofluorescence pattern,
No. (%)
Banded 12 (3.8) 11 (3.5) 23 (3.7) 22 (3.5) 35 (5.6) 80 (4.3)
Diffuse 301 (95.9) 301 (96.5) 602 (96.2) 605 (96.3) 591 (94.3) 1798 (95.6)
Not applicable 1 (0.3) 0 1 (0.2) 1 (0.2) 1 (0.2) 3 (0.2)
BCVA, mean (SD) letter scorec 66.4 (10.0) 65.6 (9.6) 66.0 (9.8) 66.1 (9.8) 66.0 (9.9) 66.0 (9.9)
<64 (worse than 20/50) 115 (37.0) 118 (38.2) 233 (37.6) 253 (40.5) 247 (39.7) 733 (39.3)
≥64 (20/50 or better) 196 (63.0) 191 (61.8) 387 (62.4) 372 (59.5) 375 (60.3) 1134 (60.7)
LLVA, mean (SD) letter scored 36.6 (16.0) 36.2 (16.3) 36.4 (16.1) 36.5 (17.6) 36.0 (16.7) 36.3 (16.8)
Low-luminance deficit (BCVA − LLVA),
mean (SD) letter scoree
29.8 (16.1) 29.3 (15.9) 29.6 (16.0) 29.6 (16.3) 30.1 (15.7) 29.7 (16.0)
Abbreviations: BCVA, best-corrected visual acuity; GA, geographic atrophy;
LLVA, low-luminance visual acuity; q4w, every 4 weeks; q6w, every 6 weeks.
a Of the total study population, race/ethnicity was identified as 0.5% (n = 9)
American Indian or Alaskan Native, 0.3% Asian (n = 5), 0.05% (n = 1) black or
African American, 0.1% (n = 2) Native Hawaiian or other Pacific Islander, 0.2%
(n = 4) multiple, and 1.8% unknown (n = 33).
b For GA area, GA contiguity, and GA lesion location, there were 626
participants for the lampalizumab q6w arm.
c For BCVA, there were 311 participants for the sham q4w arm, 309 for the sham
q6w arm, 625 for the lampalizumab q4w arm, and 622 for the lampalizumab
q6w arm.
d For LLVA, there were 304 participants for the sham q4w arm, 305 for the
sham q6w arm, 609 for the lampalizumab q4w arm, and 603 for the
lampalizumab q6w arm.
e Low-luminance deficit = BCVA – LLVA; there were 303 participants for the
sham q4w arm, 304 for the sham q6w arm, 609 for the lampalizumab q4w
arm, and 603 for the lampalizumab q6w arm.
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Chroma, 0.16 mm2 (95% CI, 0.00-0.31 mm2; P = .048 favoring
sham) for lampalizumab every 4 weeks in Spectri, 0.05 mm2
(95% CI, −0.13 to 0.24 mm2; P = .59) for lampalizumab every 6
weeks in Chroma, and 0.09 mm2 (95% CI, −0.07 to 0.24 mm2;
P = .27) for lampalizumab every 6 weeks in Spectri. Similarly,
no benefit of lampalizumab over sham was observed in robust-
ness assessments for the primary efficacy result (Table 2 and
eTables 6 and 7 in Supplement 3). Furthermore, no benefit of
lampalizumab over sham was observed for either CFI-profile bio-
marker subgroup (Figure 2 and eFigure 1 and eTable 8 in
Supplement 3). Because baseline characteristics, follow-up,
treatment adherence, and primary outcomes were similar in
Chroma and Spectri, subsequent results report pooled data, with
unpooled results in Supplement 3.
GA Enlargement by Clinical Subgroup
No consistent benefit of lampalizumab over sham was ob-
served for any subgroup (eFigures 2-4 in Supplement 3).
Best-Corrected Visual Acuity
Best-corrected visual acuity declined from baseline to week
48 in all arms of both studies (eTable 9 and eFigure 5 in
Supplement 3), with an adjusted mean BCVA letter score change
of −4.9 (95% CI, −5.8 to −4.0) for sham treatment, −4.1 (95%
CI, −5.0 to −3.2) for lampalizumab every 4 weeks, and −4.9
(95% CI, −5.8 to −3.9) for lampalizumab every 6 weeks.
Safety of Lampalizumab Treatment
No new ocular or nonocular safety signals beyond what would
be anticipated with intravitreal injections were observed with
lampalizumab through week 48 (eTables 10-19 in Supplement
3). The percentage of participants with ocular AEs and seri-
ous AEs (SAEs) were higher with lampalizumab compared with
sham treatment, in alignment with expectations for intravit-
real injections. Overall, 2.7% (17 of 619) of participants receiv-
ing the sham treatment, 6.2% (39 of 626) of participants re-
ceiving lampalizumab every 4 weeks, and 6.1% (38 of 626) of
participants receiving lampalizumab every 6 weeks experi-
enced 1 or more ocular SAEs.
Increases in intraocular pressure (IOP) were of interest
because lampalizumab was injected as 0.1 mL, twice the vol-
ume of most intravitreal injections of anti-VEGF. Incidences
of any IOP of 30 mm Hg or higher after injection, regardless of
whether the events were considered SAEs, were reported in
0.3% (2 of 618) of participants receiving the sham treatment,
8.3% (52 of 625) of participants receiving lampalizumab ev-
ery 4 weeks, and 5.6% (35 of 626) of participants receiving lam-
palizumab every 6 weeks. Increases in IOP considered to be
SAEs were reported in 0.2% (1 of 619) of participants receiv-
ing the sham treatment, 3.2% (20 of 626) of the participants
receiving lampalizumab every 4 weeks, and 2.6% (16 of 626)
of participants receiving lampalizumab every 6 weeks. The
mean preinjection IOP remained constant from baseline to
Table 2. Change in GA Area From Baseline at Week 48 in Chroma and Spectri Pooled Intent-to-Treat Populationa
Measure







Change from baseline in GA area at 48 wk, mm2
Adjusted mean (SE) 1.984 (0.043) 2.055 (0.043) 2.054 (0.043)
Difference in means (vs sham pooled) 0.071 0.070
95% CI –0.049 to 0.191 –0.050 to 0.190
Relative reduction, % –3.6 –3.5
P value .25 .25
Rate of change in GA area (growth slope) from baseline
to 48 wk, mm2/365.25 db
Adjusted mean slope (SE) 1.998 (0.045) 2.076 (0.045) 2.085 (0.045)
Difference in slopes (vs sham pooled) 0.078 0.086
95% CI –0.048 to 0.204 –0.039 to 0.212
Relative reduction, % –3.9 –4.3
P value .22 .18
Change from baseline in square root of GA area
at 48 wk, mm
Adjusted mean (SE) 0.342 (0.007) 0.349 (0.007) 0.352 (0.007)
Difference in means (vs sham pooled) 0.006 0.010
95% CI –0.013 to 0.026 –0.009 to 0.029
Relative reduction, % –1.8 –2.9
P value .53 .32
% Change from baseline in GA area at 48 wk
Adjusted mean (SE) 30.032 (0.856) 29.546 (0.859) 30.815 (0.853)
Difference in means (vs sham pooled) –0.486 0.783
95% CI –2.864 to 1.891 –1.586 to 3.153
Relative reduction, % 1.6 –2.6
P value .69 .52
Abbreviations: GA, geographic
atrophy; q4w, every 4 weeks; q6w,
every 6 weeks.
a Sample sizes shown in headers are
the number of patients included in
the mixed effects model
repeated-measures analysis. All P
values are 2-sided and calculated for
the difference between means
(lampalizumab minus sham).
b For growth slope mixed effects
model repeated-measures analysis,
there were 626 participants for the
sham pooled arm, 628 for the
lampalizumab q4w arm, and 626 for
the lampalizumab q6w arm.
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week 48 across all arms (eTable 18 and eFigure 6 in Supplement
3). Per investigator discretion, 3.1% (39 of 1252) of partici-
pants receiving lampalizumab also received paracentesis in the
study eye owing to AEs of increased IOP or transient vision loss
(5.6 procedures per 1000 injections).
Endophthalmitis occurred after 5 of 12 447 injections (0.4
events per 1000 injections [0.04%]) or in 5 of 1252 treated par-
ticipants (0.4%) through week 48. Neovascular AMD was ob-
served after randomization in 1.1% (7 of 619) of study eyes in
the group receiving the sham treatment, 1.9% (12 of 626) of
study eyes in the group receiving lampalizumab every 4 weeks,
1.9% (12 of 626) of study eyes in the group receiving lampali-
zumab every 6 weeks, 1.3% (8 of 619) of fellow eyes in the group
receiving the sham treatment, 1.6% (10 of 626) of fellow eyes
in the group receiving lampalizumab every 4 weeks, and 1.8%
(11 of 626) of fellow eyes in the group receiving lampali-
zumab every 6 weeks, with no events of bilateral neovascular
AMD (eTable 19 in Supplement 3).
Nonocular SAEs were reported in 16.6% (103 of 619) of par-
ticipants in the group receiving the sham treatment, includ-
ing 7 deaths; 19.2% (120 of 626) of participants in the group
receiving lampalizumab every 4 weeks, including 7 deaths; and
13.9% (87 of 626) of participants in the group receiving lam-
palizumab every 6 weeks, including 5 deaths.
Discussion
To our knowledge, Chroma and Spectri were the largest, most
comprehensive studies of GA conducted to date. In the pri-
mary analysis, lampalizumab did not reduce the enlarge-
ment of GA lesions from baseline at week 48 vs sham. Fur-
thermore, no benefit of lampalizumab was suggested by the
results of robustness assessments or subgroup analyses, in-
cluding by CFI-profile biomarker. No new safety signals were
observed with lampalizumab treatment, and incidences of en-
dophthalmitis, increase in IOP, or other injection-related SAEs
were low and consistent with those observed in studies of
anti-VEGF.5,6,33
The Chroma and Spectri trials provide the largest cohorts
to date of patients with bilateral GA and no CNV in either eye,
with detailed documentation of anatomical and functional out-
comes. The rates of progression of GA in Chroma and Spectri
(approximately 2 mm2 per year on average) were within the
range of previous studies (approximately 0.53-2.6 mm2 per
year),15 with differences across studies likely attributable to in-
clusion criteria reflected in the characteristics of each study co-
hort. In Chroma and Spectri, eligibility criteria included fac-
tors associated with faster GA progression, such as bilateral GA
and banded or diffuse perilesional fundus autofluorescence
patterns.15 Consistent with prior studies,15 Chroma and Spec-
tri subgroup analyses demonstrated that larger baseline GA le-
sion area, multifocal configurations, and nonfoveal GA lesions
are associated with faster rates of progression. This large data
set, from 2 multicenter global trials conducted in 23 countries,
is likely generalizable to the broader population of patients with
GA who would meet the eligibility criteria of these trials and
could serve as an important normative database for future stud-
ies and provide further insights into the natural history of GA.
The Chroma and Spectri cohorts experienced a notable de-
cline in visual function, with a mean BCVA letter score loss of
approximately 5 letters in 48 weeks. This finding under-
scores the potential burden of vision loss from GA.
Figure 2. Adjusted Mean Change From Baseline in Geographic Atrophy
(GA) Area Over Time From Baseline to 48 Weeks in Chroma and Spectri













































































































A, Overall intent-to-treat population. B, Complement factor I (CFI)–positive
population. C, CFI-negative population. The mixed effects model
repeated-measures analysis was adjusted for baseline GA area, baseline GA
lesion location, baseline GA lesion contiguity, baseline best-corrected visual
acuity category, sex, biomarker status (overall population only), and study. Error
bars indicate 95% CIs. q4w Indicates every 4 weeks; q6w, every 6 weeks.
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The safety outcomes presented here can inform future trials
through at least 1 year. Intravitreal injection volumes of 0.1 mL
were associated with low rates of increased posttreatment IOP
SAEs and no change in mean pretreatment IOP during 48 weeks,
suggesting that this volume may be given safely within a trial
setting. Also, Chroma and Spectri documented that new CNV
in patients with bilateral GA occurred in less than 2% of study
or fellow eyes. This finding is consistent with observational stud-
ies, which reported conversion rates of 2% at 2 years and 11%
at 4 years in patients with bilateral GA and no baseline CNV,34
and a conversion rate of 1.5% by 1 to 2 years in studies in which
most patients had bilateral GA.35 In contrast, for patients with
CNV in 1 eye and GA in the other, much higher rates of CNV in
the eye with GA have been reported (18% at 2 years34 and 34%-
49% at 4-5 years34,36), similar to conversion rates for eyes with
large drusen or focal hyperpigmentations.36,37 Thus, future GA
trials must consider the effect of including participants with any
history of CNV in either eye because its presence may confound
the accurate measurement of the enlargement of GA lesions and
affect visual function assessments.
The primary rationales for exploring complement inhibi-
tion in GA were the strong genetic linkage and the feasibility of
clinical trials evaluating the enlargement of GA lesions. To date,
6 molecules that act as complement pathway inhibitors have
entered clinical trials for GA, including APL-2 (target, C3), which
met its primary end point in a phase 2 trial38; CLG-561 (target,
properdin), currently in a phase 2 trial39; and avacincaptad pegol
(target, C5),40 currently in a phase 2b trial. Two other C5 inhibi-
tors, one given systemically41 and the other intravitreally,42 were
not effective in phase 2 trials. Taken together with the Chroma
and Spectri results, it remains unclear whether the comple-
ment cascade is an appropriate intraocular therapeutic target
for GA, at least through the alternative pathway via comple-
ment factor D or downstream in the cascade via C5. Geo-
graphic atrophy therapeutics investigating targets outside the
complement cascade are also in development.
Although the CFI-profile biomarker was thought to be as-
sociatedwithfasterprogressionofGAbasedontheMahalophase
2 trial of lampalizumab,29 the much larger prospective analysis
of Chroma and of Spectri does not support CFI-profile status as
a genetic biomarker for progression of GA. This finding is con-
sistent with other studies performed after the initiation of
Chroma and Spectri, which also reported no association between
CFI risk alleles and the rate of GA progression.43-45 Although it
is still not clear why such results were observed in Mahalo, in
light of the results from Chroma and Spectri, one may hypoth-
esize that they may have been related to a small sample size and
may have occurred by chance.
Strengths and Limitations
There are several strengths and limitations of these studies that
could affect the interpretation of the results. The randomiza-
tion of a large cohort; duplication of results across 2 identi-
cally designed, multicenter, double-masked, randomized clini-
cal trials; and good follow-up and adherence to the protocol
make it less likely that confounding or bias affected these
topline results. However, the results apply only to 48 weeks
of treatment and may not apply to all cases of GA. Based on
the inclusion and exclusion criteria of these trials, they may
not apply to patients with smaller or larger lesions, unilateral
GA, autofluorescence patterns other than banded or diffuse,
eyes with current or prior CNV, GA from causes other than AMD,
or earlier disease stages.
Conclusions
In 2 identically designed phase 3 trials, lampalizumab, a
selective complement factor D inhibitor, did not reduce the en-
largement of GA lesions vs sham. The results highlight both
the potential burden of vision loss facing patients with bilat-
eral GA and the substantial retinal tissue loss that occurs
during 48 weeks. Further analysis of Chroma and Spectri, in-
cluding genotype-phenotype correlations enabled by whole-
genome sequencing, may yield additional insights into AMD
pathophysiology and support future clinical trials.
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